Detection of Neutralizing Antibody Against SARS-CoV-2 in RT-PCR Confirmed COVID-19 Patient with Diverse Disease Severity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210329003

Enrollment

Registered

2021-03-29

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 COVID-19

Interventions

According to WHO clinical management of COVID19 2020 Patient whom categorized as mild disease will enrolled in this group,According to WHO clinical management of COVID19 2020 Patient whom categorized

Diagnostic,Diagnostic

COVID-19 patient with mild disease manifestation,COVID-19 patient with moderate/severe/critical disease manifestation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RT-PCR positive confirmed COVID-19 patient admitted in King Chulalongkorn Memorial Hospital from February 2020 to May 2020

Exclusion criteria

Exclusion criteria: Patient who loss follow up Patient who denied from the study

Design outcomes

Primary

Measure	Time frame
%inhibition at the time COVID-19 diagnosed by RT-PCR The study aims to measure the %inhibition of neutralizing antibody measure by surrogate virus neutralization test (sVNT) (cPassTM, GenScript, USA) in RT-PCR confirmed COVID-19 patients.	—

Secondary

Measure	Time frame
%inhibition 3, 6, 9, 12 months after diagnosis unpaired t-test	—

Countries

Thailand

Contacts

Public ContactThapakorn Sirawattanachai

King Chulalongkorn Memorial Hospital

bug_life@hotmail.com0819883781

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026